American Assets Investment Management LLC held its position in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 10,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. American Assets Investment Management LLC’s holdings in Shire PLC were worth $1,653,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Checchi Capital Advisers LLC raised its stake in Shire PLC by 18.2% in the second quarter. Checchi Capital Advisers LLC now owns 1,467 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 226 shares during the period. Morningstar Investment Services LLC raised its stake in Shire PLC by 91.9% in the second quarter. Morningstar Investment Services LLC now owns 16,913 shares of the biopharmaceutical company’s stock valued at $2,795,000 after buying an additional 8,101 shares during the period. Trillium Asset Management LLC raised its stake in Shire PLC by 153.8% in the second quarter. Trillium Asset Management LLC now owns 48,001 shares of the biopharmaceutical company’s stock valued at $7,933,000 after buying an additional 29,087 shares during the period. Alpine Woods Capital Investors LLC raised its stake in Shire PLC by 28.2% in the second quarter. Alpine Woods Capital Investors LLC now owns 81,700 shares of the biopharmaceutical company’s stock valued at $13,503,000 after buying an additional 17,971 shares during the period. Finally, Dividend Assets Capital LLC raised its stake in Shire PLC by 45.9% in the second quarter. Dividend Assets Capital LLC now owns 320,974 shares of the biopharmaceutical company’s stock valued at $53,047,000 after buying an additional 100,927 shares during the period. 20.22% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC (NASDAQ:SHPG) opened at 148.615 on Wednesday. Shire PLC has a one year low of $147.28 and a one year high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.53 by $0.20. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company had revenue of $3.75 billion during the quarter. During the same period in the prior year, the company posted $3.38 EPS. The firm’s revenue was up 54.2% on a year-over-year basis. Equities analysts predict that Shire PLC will post $14.92 EPS for the current year.
The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is presently 40.63%.
TRADEMARK VIOLATION NOTICE: “American Assets Investment Management LLC Has $1,653,000 Stake in Shire PLC (SHPG)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/08/16/american-assets-investment-management-llc-has-1653000-stake-in-shire-plc-shpg.html.
SHPG has been the subject of several analyst reports. Royal Bank Of Canada set a $221.00 price objective on Shire PLC and gave the stock a “buy” rating in a research note on Thursday, May 18th. Sanford C. Bernstein restated a “market perform” rating and issued a $210.00 price objective on shares of Shire PLC in a research note on Thursday, July 13th. HSBC Holdings plc upgraded Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. Finally, Stifel Nicolaus cut their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research note on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and a consensus target price of $222.27.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
